Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 vs QL1604 consolidation therapy after chemoradiotherapy in limited-stage small cell lung cancer
CTR20250450Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QL1706, iparomlimab in small cell lung cancer (SCLC), sponsored by Qilu Pharmaceutical. Started Apr 2025; status: active.
02
Drugs
QL1706iparomlimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20250450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250450.